Aeon Biopharma Inc.’s stock plunged 53% in intraday trading May 3 on the company’s announcement of disappointing results from testing of its migraine drug. The Irvine-based clinical-stage company (NYSE: AEON) said its ABP-450 treatment for the prevention of chronic migraine did no better than placebo in a Phase 2 trial.
AEON Biopharma (AEON) Reports Prelim Top-Line Results from Phase 2 Analysis of ABP-450 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AEON Biopharma (NASDAQ:AEON) Shares Up 7.7% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
AEON Biopharma (AEON) Reports Topline Results from Phase 2 Trial of ABP-450 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.